The “Next Bitcoin”? 10 CENT Crypto Set to Explode

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Dennis J. Selkoe net worth and biography

Dennis Selkoe Biography and Net Worth

Director of Prothena

Dr. Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital in Boston, positions he has held since 2000 and 1985, respectively. He has served on the faculty at Harvard Medical School since 1978. Dr. Selkoe was the principal founding scientist and served as a director of Athena Neurosciences, Inc. until it was acquired by Elan Corporation, plc in 1996. He has received numerous honors, including the Mathilde Solowey Award in the Neurosciences (NIH), the Potamkin Prize (American Academy of Neurology), the A.H. Heineken Prize for Medicine, the Pioneer Award and the Lifetime Achievement Award (Alzheimer’s Association), the George C. Cotzias Lecture of the American Academy of Neurology and the Ulysses Medal of University College Dublin. Dr. Selkoe is a Fellow of the American Academy of Neurology, the American Association for the Advancement of Science and the American College of Physicians, an elected member of the National Academy of Medicine and a director of the Foundation for Neurologic Diseases. He served as a director of Elan from 1996 to 2013. Dr. Selkoe earned his B.A. from Columbia University and his M.D. from the University of Virginia. He has served on our Board since 2013.

What is Dennis J. Selkoe's net worth?: The estimated net worth of Dennis J. Selkoe is at least $59,289.80 as of July 3rd, 2023. Mr. Selkoe owns 2,845 shares of Prothena stock worth more than $59,290 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Selkoe may own. Learn More about Dennis J. Selkoe's net worth.
How do I contact Dennis J. Selkoe?: The corporate mailing address for Mr. Selkoe and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Dennis J. Selkoe's contact information.
Has Dennis J. Selkoe been buying or selling shares of Prothena?: Dennis J. Selkoe has not been actively trading shares of Prothena over the course of the past ninety days. Learn More on Dennis J. Selkoe's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 33 times. They sold a total of 307,333 shares worth more than $20,322,452.52. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.2% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Dennis J. Selkoe Insider Trading History at Prothena

Dennis J. Selkoe Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $20.84

$20.34

$21.18

50 Day Range

MA: $25.52

$20.56

$30.30

2 Week Range

Now: $20.84

$19.65

$79.65

Volume

70,239 shs

Average Volume

744,574 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad